Breadcrumb

null Ahmad Haidar, PhD

Scientist, RI-MUHC

Metabolic Disorders and Complications Program

Centre for Translational Biology

Associate Professor, Department of Biomedical Engineering, Faculty of Medicine and Health Sciences, McGill University

 

Keywords


Type 1 diabetes • clinical research • artificial pancreas systems • automated insulin delivery system • randomized controlled trials

Research Focus


My research focuses on developing artificial pancreas systems for type 1 diabetes. The artificial pancreas is a medical device that automatically regulates glucose levels for patients with type 1 diabetes. The artificial pancreas is composed of a glucose sensor, an infusion portable pump, and an advanced mathematical dosing algorithm that controls hormonal delivery based on the sensor readings. Using commercial pumps and sensors, my lab develops and clinically tests novel control algorithms that are the crux of the artificial pancreas. We also conduct clinical trials to assess different configurations of the artificial pancreas, the performance of the artificial pancreas during exercise and meals, and the performance of the artificial pancreas in special patient populations and during long-term use. As the artificial pancreas is considered the most promising therapy for type 1 diabetes, this work has great potential to improve patients’ quality of life.

Selected Publications


Click on Pubmed to see my current publications list

  • Haidar, Ahmad, et al. "Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial." CMAJ 185.4 (2013): 297-305.

  • Haidar, Ahmad, et al. "Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial." The lancet Diabetes & endocrinology 3.1 (2015): 17-26.

  • Haidar, Ahmad, et al. "Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial." The lancet Diabetes & endocrinology 3.8 (2015): 595-604.

  • Haidar, Ahmad. "The artificial pancreas: How closed-loop control is revolutionizing diabetes." IEEE Control Systems Magazine 36.5 (2016): 28-47.

  • Peters, T. M., and A. Haidar. "Dual‐hormone artificial pancreas: benefits and limitations compared with single‐hormone systems." Diabetic Medicine 35.4 (2018): 450-459.